Panoptes Pharma (PP-001 marketing rights in two European countries) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Panoptes Pharma (PP-001 marketing rights in two European countries) General Information

Description

A marketing rights for pre-clinical development molecule in Austria. The asset features marketing rights of PP-001, a small molecule which is currently in preclinical development as potential next generation treatment for several inflammatory eye diseases including non-infectious uveitis in two European countries.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Reisnerstraße 34/1
  • Vienna, 1030
  • Austria
Primary Industry
Buildings and Property
Other Industries
Other Commercial Services
Acquirer
Laboratoires Leurquin Mediolanum
Corporate Office
  • Reisnerstraße 34/1
  • Vienna, 1030
  • Austria

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Panoptes Pharma (PP-001 marketing rights in two European countries) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Panoptes Pharma (PP-001 marketing rights in two European countries)‘s full profile, request access.

Request a free trial

Panoptes Pharma (PP-001 marketing rights in two European countries) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Panoptes Pharma (PP-001 marketing rights in two European countries)‘s full profile, request access.

Request a free trial

Panoptes Pharma (PP-001 marketing rights in two European countries) FAQs

  • Where is Panoptes Pharma (PP-001 marketing rights in two European countries) headquartered?

    Panoptes Pharma (PP-001 marketing rights in two European countries) is headquartered in Vienna, Austria.

  • What industry is Panoptes Pharma (PP-001 marketing rights in two European countries) in?

    Panoptes Pharma (PP-001 marketing rights in two European countries)’s primary industry is Buildings and Property.

  • Is Panoptes Pharma (PP-001 marketing rights in two European countries) a private or public company?

    Panoptes Pharma (PP-001 marketing rights in two European countries) is a Private company.

  • What is Panoptes Pharma (PP-001 marketing rights in two European countries)’s current revenue?

    The current revenue for Panoptes Pharma (PP-001 marketing rights in two European countries) is .

  • Who are Panoptes Pharma (PP-001 marketing rights in two European countries)’s investors?

    Panoptes Pharma has invested in Panoptes Pharma (PP-001 marketing rights in two European countries).

  • When was Panoptes Pharma (PP-001 marketing rights in two European countries) acquired?

    Panoptes Pharma (PP-001 marketing rights in two European countries) was acquired on 12-Feb-2015.

  • Who acquired Panoptes Pharma (PP-001 marketing rights in two European countries)?

    Panoptes Pharma (PP-001 marketing rights in two European countries) was acquired by Laboratoires Leurquin Mediolanum.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »